Newsroom
153 articles
Featured Non-arteritic anterior ischemic optic neuropathy, or NAION, is a very rare eye condition that causes vision loss; it affects 1 in 10,000 patients taking Semaglutide for treatment of…
Featured We now live in a time where innovation & technology are shaping our future from mobile phones to life saving inventions. The UK government has been investing in…
Featured As of 16th of May 2025 Guselkumab (Tremfya) has been approved for the treatment of Crohn’s disease & Ulcerative colitis. However, it was initially used for the treatment…
Featured With the rising risk of antibiotics resistance, EMA’s human medicines committee (CHMP) has decided on readjusting the use of some antibiotics like azithromycin and limiting its indications, in…
Featured With the AI being integrated in almost everything nowadays, FDA has decided to dive in and also integrate AI in their practice. AI has proven to be an…
Featured EMA’s safety committee, Pharmacovigilance Risk Assessment Committee (PRAC) recent review revealed negative mental health impact of finasteride and dutasteride on patients taking it for anti-hair loss purposes. Finasteride…
Featured As part of global efforts to protect the environment, the Medicines and Healthcare products Regulatory Agency (MHRA) is playing a role by supporting changes to inhalers used by…
Featured The FDA has just recently approved a new blood test called The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, that helps with the early detection of Alzheimer’s diseases in…
Featured With Kaftrio being used for treatment of patients with Cystic Fibrosis, comes serious negative impact on patient’s psychological state. As of 25 February 2025, the MHRA received 300…
Featured The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for obecabtagene autoleucel (Aucatzyl)—a CAR T-cell therapy—for the treatment of adult patients with relapsed or…
Featured The U.S. Food and Drug Administration (FDA) has taken the initiative to stop the use of concentrated ingestible fluoride present in prescription drugs of children. Toddlers or infants…
Featured As of 30 April 2025, a new formulation for Nivolumab has been approved by The Medicines and Healthcare products Regulatory Agency (MHRA) making the treatment process much simpler…
Featured The UK’s Medicines & Healthcare Products Regulatory agency has approved Acoramidis (Beyonttra) for the treatment of adult patients with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM), including both wild-type…
Featured Asthma Patients who rely solely on their blue inhalers may be putting their health at greater risk. That’s why The Medicines and Healthcare products Regulatory Agency (MHRA) is…
Featured The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Omaveloxolone (Skyclarys) as the first-ever treatment for Friedreich’s ataxia in patients aged 16 and older, a major…
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP
Request Consultation
Submit RFI/RFP